Literature DB >> 7044536

Trial of tamoxifen at a dose of 40 mg daily after disease progression during tamoxifen therapy at a dose of 20 mg daily.

J F Stewart, M J Minton, R D Rubens.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7044536

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  6 in total

Review 1.  Endocrine therapy of metastatic breast cancer.

Authors:  A Manni
Journal:  J Endocrinol Invest       Date:  1989-05       Impact factor: 4.256

2.  On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer.

Authors:  E Petru; D Schmähl
Journal:  Klin Wochenschr       Date:  1987-10-15

Review 3.  Tamoxifen as adjuvant therapy in breast cancer. Current status.

Authors:  P N Plowman
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

4.  The value of high dose tamoxifen in postmenopausal breast cancer patients progressing on standard doses: a pilot study.

Authors:  S M Watkins
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

5.  Tamoxifen metabolism: pharmacokinetic and in vitro study.

Authors:  M C Etienne; G Milano; J L Fischel; M Frenay; E François; J L Formento; J Gioanni; M Namer
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

6.  A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.

Authors:  D G Bratherton; C H Brown; R Buchanan; V Hall; E M Kingsley Pillers; T K Wheeler; C J Williams
Journal:  Br J Cancer       Date:  1984-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.